Assuntos
Hansenostáticos/uso terapêutico , Hanseníase/tratamento farmacológico , Hanseníase/epidemiologia , Resistência Microbiana a Medicamentos/efeitos dos fármacos , Resistência Microbiana a Medicamentos/fisiologia , Humanos , Índia/epidemiologia , Hansenostáticos/farmacologia , Mycobacterium leprae/efeitos dos fármacosAssuntos
Anti-Infecciosos/uso terapêutico , Resistência Microbiana a Medicamentos/efeitos dos fármacos , Infecções por Mycoplasma/tratamento farmacológico , Mycoplasma hominis/efeitos dos fármacos , Infecções por Ureaplasma/tratamento farmacológico , Ureaplasma urealyticum/efeitos dos fármacos , Adolescente , Adulto , Anti-Infecciosos/farmacologia , Feminino , Humanos , Masculino , Infecções por Mycoplasma/diagnóstico , Mycoplasma hominis/isolamento & purificação , Infecções por Ureaplasma/diagnóstico , Ureaplasma urealyticum/isolamento & purificação , Adulto JovemRESUMO
Mycobacterium aurum (M. aurum) is an environmental mycobacteria that has previously been used in studies of anti-mycobacterial drugs due to its fast growth rate and low pathogenicity. The M. aurum genome has been sequenced and assembled into 46 contigs, with a total length of 6.02Mb containing 5684 annotated protein-coding genes. A phylogenetic analysis using whole genome alignments positioned M. aurum close to Mycobacterium vaccae and Mycobacterium vanbaalenii, within a clade related to fast-growing mycobacteria. Large-scale genomic rearrangements were identified by comparing the M. aurum genome to those of Mycobacterium tuberculosis and Mycobacterium leprae. M. aurum orthologous genes implicated in resistance to anti-tuberculosis drugs in M. tuberculosis were observed. The sequence identity at the DNA level varied from 68.6% for pncA (pyrazinamide drug-related) to 96.2% for rrs (streptomycin, capreomycin). We observed two homologous genes encoding the catalase-peroxidase enzyme (katG) that is associated with resistance to isoniazid. Similarly, two embB homologues were identified in the M. aurum genome. In addition to describing for the first time the genome of M. aurum, this work provides a resource to aid the use of M. aurum in studies to develop improved drugs for the pathogenic mycobacteria M. tuberculosis and M. leprae.
Assuntos
Antituberculosos/farmacologia , Genoma Bacteriano/genética , Mycobacterium leprae/efeitos dos fármacos , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium/genética , Proteínas de Bactérias/metabolismo , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Resistência Microbiana a Medicamentos/efeitos dos fármacos , Resistência Microbiana a Medicamentos/genética , Testes de Sensibilidade Microbiana , Mycobacterium/efeitos dos fármacos , Mycobacterium/enzimologia , Mycobacterium/metabolismo , Pentosiltransferases/metabolismo , Peroxidases/metabolismo , FilogeniaRESUMO
The reported number of registered leprosy patients worldwide declined with the introduction of multidrug therapy. However, the emergence of rifampicin resistance in leprosy patients engenders difficulties for an individual patient, and its dissemination could pose a threat to leprosy control. This study reports an elderly patient who was diagnosed with rifampicin-resistant lepromatous leprosy. This case indicates that inadequate treatment and poor compliance may eventually result in rifampicin resistance in Mycobacterium leprae and clinical relapse.